| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Trade names | mNEXSPIKE[1] |
| Routes of administration | Intramuscular |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
mRNA-1283, sold under the brand namemNEXSPIKE, is aCOVID-19 vaccine candidate developed byModerna.[2][3][4]
Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible withvaccine storage in a standard refrigerator, rather than low temperature freezers.[5] Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.[6]
In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[7] As of May 2024, the vaccine candidate is in Phase 3 clinical trials, with an estimated completion date of late August 2024.[8] Preliminary results from this trial indicated the vaccine produced a strong immune response, especially in patients over 65, who are at greater risk for severe outcomes from COVID-19.[9]
mRNA-1283 was approved by theFood and Drug Administration on May 30, 2025, under the name "mNEXSPIKE", for use in adults 65 years or older and individuals 12-64 years old with at least one comorbidity.[10][4][11]
